One of the concerns that I had when I read about what IBRX was doing was their scattershot involvement with so many different cancer treatments and trials. The problem with a prerevenue company is they can't afford to do all that research. Not even close, they don't have $20 billion to invest. On its face, it seemed absurd to have so many phase 1 trials but no cash to fund the phase 2/3 trails that would necessarily follow. But then I figured it out.
PSS is trying to use these trails to get clinical data and recruit other companies into believing in the general application of Anktiva to all cancers. He's doing this as a marketing strategy. He's looking for investment from one of the majors. That's the gig. Pfizer or similar (preferably not Pfizer) is going to come into the stock and take a position, and they will bring the funding for all the different trials that have to be done. He's demonstrating the broad utility of the molecule IOT bring in a partner who can broadly commercialize the thing.
5 out of 5 with GBM for refractive is outstanding. It's off the charts. GBM is s death sentence, This is unprecedented. It's a small thing, but it's going to get some attention over time. People who know what this means are going to start paying attention. It fits broadly into the category of what most people would call magic. It's a big deal. Huge.
It's a strategy, and it's deliberate. It's the solution to the dilution. It solves both the shareholder issue, and the issue of getting better medical care to people who are sick. It's kind of genius, mitigated by the fact that he first thought he could do it all on his own. I'm starting to feel like I should start DCA into the thing.